An update on <i>Saccharomyces boulardii</i>

Hanna Szajewska

doi:10.5114/pg.2012.33042

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

6/2012
vol. 7

Send email

Copy url:

abstract:

Review paper

An update on Saccharomyces boulardii

Hanna Szajewska

Prz Gastroenterol 2012; 7 (6): 351–358

DOI: https://doi.org/10.5114/pg.2012.33042

Online publish date: 2013/01/31

View full text Get citation

PlumX metrics:

Not all probiotics are created equal. The efficacy and safety of each probiotic microorganism has to be evaluated separately. This paper aims to systematically evaluate the effectiveness and safety of Saccharomyces boulardii in children and adults. The MEDLINE and The Cochrane Library (both up to June 2012) were searched for randomized controlled trials or their meta-analyses relevant to S. boulardii. Available evidence documents that S. boulardii is effective in treating acute gastroenteritis in children and preventing antibiotic-associated diarrhoea in children and adults treated with antibiotics for any reason. S. boulardii is probably effective in preventing Clostridium difficile infection and for the prevention of traveller’s diarrhoea. In patients with Helicobacter pylori infection, there is evidence to recommend the use of S. boulardii along with standard triple therapy as an option for increasing the eradication rates and decreasing overall therapy-related side effects, particularly diarrhoea.

keywords:

An update on Saccharomyces boulardii

Hanna Szajewska

probiotics, microflora, microbiota